Latest news with #FortisHospitals
Time of India
20-07-2025
- Health
- Time of India
41st anniversary of The Times of India, Bengaluru: World-class treatment at a fraction of the cost
From being home to just a handful of govt hospitals in the 1980s to emerging a world-renowned medical tourism destination, Bengaluru's transformation in the healthcare sector is nothing short of extraordinary. Known primarily for its booming IT sector, the city is now drawing global attention for its excellence in the medical field – combining affordability with advanced infrastructure. The city now boasts of some of the finest multi-speciality and superspeciality hospitals in Asia, attracting patients from across Africa, the Middle East, South Asia, Mauritius and the Maldives. World-class doctors, cutting-edge technology, and a supportive ecosystem have all turned Bengaluru into a medical hub where healing meets hospitality. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru Medical value travel Akshay Oleti, the vice-president and business head at Fortis Hospitals, told TOI there are three major factors driving Bengaluru's medical tourism boom. 'First, the weather. Patients who come to India for treatment often bring their families along. The city's cosmopolitan nature and year-round moderate climate make it an ideal choice. The second reason is connectivity. Over the past few years, we've seen a surge in international connectivity, making the city more accessible. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Up to 70% off | Shop Sale Libas Undo For any medical tourist, fewer flight changes matter a lot. Third, the availability of high-end, modern medical care. We're seeing largescale investments in robotics, minimally invasive surgeries, and advanced daycare procedures,' he explained. He further said: 'We've seen a sharp rise in patients from countries such as Oman, UAE, Qatar, Yemen, Kenya, Nigeria, and Ethiopia. With investments in robotics, advanced diagnostics, and day-care procedures, Bengaluru now offers treatments that once required long hospital stays, with better outcomes and shorter recovery windows.' The range of specialities is wide. Neurology, for instance, is a major draw, with deep brain stimulation, spine tumour operations, and movement disorder surgeries gaining traction among international patients. Dr Madhu Sasidhar, the president and CEO of Apollo Hospitals, echoed Oleti's views: 'We are seeing more international patients opting for Bengaluru due to its advanced infrastructure, expert medical teams, and efficient systems. Our hospitals offer precision oncology, robotic-assisted surgeries, and targeted radiation therapies, along with patient-friendly services such as day-care chemotherapy, all of which appeal to those seeking faster, more comfortable treatment journeys. ' He added that supportive care, including rehabilitation, counselling, and wellness therapies such as yoga and Ayurveda are often built into the recovery process, giving Bengaluru an edge over other global destinations. The shift is visible across multiple specialities. Dr Ranjan Shetty, the medical director at Sparsh Hospitals, spoke about a consistent rise in patients from Africa, the Middle East, and South Asia, especially for complex orthopaedic surgeries, neuro interventions, transplants, and oncology. 'We're seeing between 2,000 and 3,000 international patients annually. What brings them here is a combination of clinical depth, technology, and compassionate care,' he said. While patients from Bangladesh used to constitute a major chunk of foreign patients earlier, recent visa delays have impacted their numbers. 'Proximity and affordability' Karthik Rajagopal, the group COO at Manipal Hospitals, said: 'Bengaluru is always a preferred destination for international patients coming to India, given the accessibility of medical facilities. There are patients who come from the SAARC countries, Nepal, Sri Lanka, the Middle East, and Africa, each bringing unique cultural perspectives to create a vibrant, multicultural healing environment.' Rajagopal further said: 'Patients from Bangladesh and the Maldives form a significant portion of Manipal Hospitals' international patient base, owing to its proximity and affordability. The Maldives, with limited advanced medical infrastructure, sends patients here seeking specialised care.' According to Dr Simanta G. Sharma, the head of healthcare development and transformation at Ramaiah Memorial Hospital, Bengaluru is emerging the healthcare capital of India largely because of easy availability and quality of healthcare establishments across the city. 'It's not just one or two hospitals. We have a network of multi-speciality and super-speciality hospitals that offer world-class services. These institutions are at par with some of the best healthcare systems globally, including those in the UK, US, and western Europe,' Dr Sharma said. And yet, the cost of treatment here is significantly lower, often just a tenth of what it is in the West. 'So, for medical value travellers, Bengaluru is an unbeatable combination: global standards of care at a fraction of the price,' Dr Sharma added. Rising demand for eye care Super-speciality eye care is one of the key areas where Bengaluru has emerged as a medical destination of choice for patients from all over the world. Explaining this trend, Dr Sushmitha Sriganesh from Nethradhama Super Speciality Eye Hospital said: 'We treat more than 400 international patients every year, largely from Kenya, Nigeria, Zambia, Ghana, Mauritius, and the Middle East. Many come to us for advanced cataract surgeries, LASIK, SMILE, glaucoma cure, and oculoplasty. These are procedures that may be unavailable or unaffordable in their home countries. ' Fertility clinics in demand Fertility is another area witnessing increasing global demand. Abhishek Aggrawal, the CEO of Birla Fertility & IVF, says the Bengaluru centre is seeing a surge in overseas interest, particularly from Oman, Iraq, and Sudan. 'These patients are not just looking for affordability, they're looking for expertise and trust. Our patients come for IVF, fertility preservation, and advanced diagnostics, and what they value most is the personalised care and end-to-end support we offer — from treatment planning to accommodation and language coordination,' Agarwal said.
India Gazette
05-07-2025
- Business
- India Gazette
Teleflex signs MoU with Fortis Hospitals in India to create a UroLift Center of Education
HT Syndication New Delhi [India], July 5: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift System. The UroLift System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life. The UroLift System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLift System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment. 'At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, 'The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care.' Dr. Mohan Keshavamurthy, Principal Director - Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.' These training programs for the UroLift System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift System The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines. More than 500,000 men have been treated with the UroLift System in select markets worldwide. Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study. (ADVERTORIAL DISCLAIMER: The above press release has been provided by HT Syndication. ANI will not be responsible in any way for the content of the same)
Business Standard
05-07-2025
- Business
- Business Standard
Teleflex signs MoU with Fortis Hospitals in India to create a UroLift Center of Education
HT Syndication New Delhi [India], July 5: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift System. The UroLift System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life. The UroLift System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue. The UroLift System provides rapid symptom relief and preserves sexual function. Typically, no catheter is required after the treatment. "At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care," said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, "The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care." Dr. Mohan Keshavamurthy, Principal Director - Renal Sciences, Fortis Hospitals, Bengaluru, said, "Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice." These training programs for the UroLift System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift System The UroLift System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction. Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines. More than 500,000 men have been treated with the UroLift System in select markets worldwide. Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
The Print
04-07-2025
- Health
- The Print
Teleflex signs MoU with Fortis Hospitals in India to create a UroLiftTM Center of Education
New Delhi [India], July 4: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift™ System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift™ System. The UroLift™ System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life1. The UroLift™ System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue 2,3. The UroLift™ System provides rapid symptom relief 2 and preserves sexual function 5*. Typically, no catheter is required after the treatment 2,4. 'At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care,' said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, 'The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care.' Dr. Mohan Keshavamurthy, Principal Director – Renal Sciences, Fortis Hospitals, Bengaluru, said, 'Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice.' These training programs for the UroLift™ System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift™ System The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. 2,3 The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. 7 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*3,5,6 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence 2. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines 9. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.8 Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rusch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study. (ADVERTORIAL DISCLAIMER: The above press release has been provided by HT Syndication. ANI will not be responsible in any way for the content of the same) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
Business Standard
04-07-2025
- Health
- Business Standard
Teleflex signs MoU with Fortis Hospitals in India to create a UroLiftTM Center of Education
HT Syndication New Delhi [India], July 4: Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has signed a Memorandum of Understanding with Fortis Hospitals Bengaluru to create the UroLift Center of Education in India. Teleflex announced that 500 patients have been treated with its UroLift™ System in India and Fortis Hospitals is the first hospital to treat about 100 BPH patients with the UroLift™ System. The UroLift™ System uses a minimally invasive approach to treating Benign Prostatic Hyperplasia (BPH). BPH is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life1. The UroLift™ System is the only leading BPH procedure that does not require heating, cutting, removal, or destruction of prostate tissue 2,3. The UroLift™ System provides rapid symptom relief 2 and preserves sexual function 5*. Typically, no catheter is required after the treatment 2,4. "At Teleflex, we believe that education is the foundation of progress in healthcare. Our collaboration with Fortis Hospitals will empower medical professionals with advanced knowledge and hands-on training, ultimately improving patient care," said Arun Kaushik, Managing Director, South Asia, Teleflex. Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare Limited stated, "The healthcare landscape continues to evolve, and more minimally invasive therapies continue to emerge. At Fortis, we always strive to offer superior technologies to our patients. This educational initiative in association with Teleflex is another testament to our commitment to quality patient care." Dr. Mohan Keshavamurthy, Principal Director - Renal Sciences, Fortis Hospitals, Bengaluru, said, "Through this collaboration, we are committed to helping Urologists acquire requisite skill to optimise individualised treatment solutions such as UROLIFT for patients requiring Endoscopic surgical solutions for BPH and enhancing outcomes thereof. The programme is designed to provide a comprehensive training program to Urologists to ensure careful selection and safe delivery of the UroLift System to patients in their practice." These training programs for the UroLift™ System will be conducted at Fortis Hospitals, Bannerghatta Road, Bengaluru. About the UroLift™ System The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100 cc in men 50 years and above in India. In India, prostatic urethral lift like UroLift is an optional therapy and shall be offered as an alternative to patients presenting with moderate-to-severe LUTS who failed to respond to medical management and who are not tolerant or compliant to medical management (GR optional). The UroLift permanent implants, delivered during the procedure, relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. 2,3 The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe. 7 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.*3,5,6 Most common adverse events are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence 2. Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines as well as an optional procedure for BPH management in Urological Society of India guidelines 9. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.8 Learn more at Rx only. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in the world of healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare. Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rusch™, UroLift™ and Weck™ - trusted brands united by a common sense of purpose. At Teleflex, we are empowering the future of healthcare. For more information, please visit References: 1. Speakman et al. 2014 BJUI International 2. Roehrborn, J Urology 2013 3. AUA BPH Guidelines 2003, 2020 4. Shore, Can J Urol 2014 5. Roehrborn, Can J Urol 2017 6. McVary, J Sex Med 2016 7. Rukstalis, Prostate Cancer and Prostatic Dis 2018 8. Management estimate based on product sales and average units per procedure 9. Urological Society of India BPH Guidelines, 2019 *No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study.
